[1] Eslam M, Sanyal A J, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.
[2] Rinella M, Lazarus J, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023.
[3] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5): 418-434.
[4] Le M H, Yeo Y H, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(12): 2809-2817.
[5] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347.
[6] Powell E E, Wong V W, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.
[7] Diehl A M, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072.
[8] Machado M V, Diehl A M. Pathogenesis of nonalcoholic steatohepatitis[J]. Gastroenterology, 2016, 150(8): 1769-1777.
[9] Liu Z, Wang Q, Huang H, et al. Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study[J]. Diabetol Metab Syndr, 2023, 15(1): 27.
[10] Sun Q, Zhang T, Manji L, et al. Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis[J]. Clin Epidemiol, 2023, 15: 683-693.
[11] Wei F, Li J, Chen C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study[J]. Front Endocrinol (Lausanne), 2020, 11: 179.
[12] Yang C, Yang S, Xu W, et al. Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: a retrospective cohort study[J]. PLoS One, 2017, 12(5): e177249.
[13] Zhou F, He X, Liu D, et al. Association between serum ferritin and uric acid levels and nonalcoholic fatty liver disease in the Chinese population[J]. PeerJ, 2023, 11: e16267.
[14] Zhao H, Qiu X, Li H Z, et al. Association between serum uric acid to HDL-cholesterol ratio and nonalcoholic fatty liver disease risk among Chinese adults[J]. Biomed Environ Sci, 2023, 36(1): 1-9.
[15] Wang X, Han Y, Liu Y, et al. Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol[J]. BMC Gastroenterol, 2022, 22(1): 419.
[16] Yang H, Li D, Song X, et al. Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study[J]. J Transl Med, 2018, 16(1): 285.
[17] Lin H, Li Q, Liu X, et al. Liver fat content is associated with elevated serum uric acid in the Chinese middle-aged and elderly populations: Shanghai Changfeng study[J]. PLoS One, 2015, 10(10): e140379.
[18] Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis[J]. Acta Med Indones, 2017, 49(2): 136-147.
[19] Liu J, Xu C, Ying L, et al. Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults[J]. Hepatol Res, 2017, 47(3): E104-E112.
[20] Petta S, Camma C, Cabibi D, et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2011, 34(7): 757-766.
[21] Kim K, Kang K, Sheol H, et al. The association between serum uric acid levels and 10-year cardiovascular disease risk in non-alcoholic fatty liver disease patients[J]. Int J Environ Res Public Health, 2022, 19(3):1042.
[22] Gong S, Song J, Wang L, et al. Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2016, 28(2): 132-138.
[23] Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Clin Biochem, 2016, 49(7-8): 636-642.
[24] Wijarnpreecha K, Panjawatanan P, Lekuthai N, et al. Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis[J]. Liver Int, 2017, 37(6): 906-918.
[25] Zheng X, Gong L, Luo R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017, 16(1): 202.
[26] Lanaspa M A, Sanchez-Lozada L G, Choi Y J, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver[J]. J Biol Chem, 2012, 287(48): 40732-40744.
[27] Wan X, Xu C, Lin Y, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J]. J Hepatol, 2016, 64(4): 925-932.
[28] Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance[J]. Biochem Biophys Res Commun, 2014, 447(4): 707-714.
[29] Finck B N. Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis[J]. Diabetes, 2018, 67(12): 2485-2493.
[30] Ramos-Tovar E, Muriel P. NLRP3 inflammasome in hepatic diseases: a pharmacological target[J]. Biochem Pharmacol, 2023, 217: 115861.
[31] Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds[J]. J Hepatol, 2015, 62(6): 1412-1419.
[32] Toledo-Ibelles P, Gutierrez-Vidal R, Calixto-Tlacomulco S, et al. Hepatic accumulation of hypoxanthine: a link between hyperuricemia and nonalcoholic fatty liver disease[J]. Arch Med Res, 2021, 52(7): 692-702.
[33] Zhang J, Xu C, Zhao Y, et al. The significance of serum xanthine oxidoreductase in patients with nonalcoholic fatty liver disease[J]. Clin Lab, 2014, 60(8): 1301-1307.
[34] Lanaspa M A, Sanchez-Lozada L G, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver[J]. PLoS One, 2012, 7(10): e47948.
[35] Guma M, Dadpey B, Coras R, et al. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes[J]. Arthritis Res Ther, 2022, 24(1): 175.
[36] Nishikawa T, Nagata N, Shimakami T, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice[J]. Sci Rep, 2020, 10(1): 815.
[37] Kakimoto M, Fujii M, Sato I, et al. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats[J]. J Appl Biomed, 2023, 21(2): 80-90.
[38] Al-Shargi A, El Kholy A, Adel A, et al. Allopurinol versus febuxostat: a new approach for the management of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease[J]. Biomedicines, 2023, 11(11):3074.
[39] Sun D Q, Wu S J, Liu W Y, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease[J]. Expert Opin Ther Targets, 2016, 20(3): 375-387.
[40] Tang Y, Xu Y, Liu P, et al. No evidence for a causal link between serum uric acid and nonalcoholic fatty liver disease from the Dongfeng-Tongji cohort study[J]. Oxid Med Cell Longev, 2022, 2022: 6687626. |
